Form 4: REGENXBIO CMO Sells Shares Under 10b5-1 Plan

REGENXBIO's Chief Medical Officer, Steve Pakola, sold 5,124 shares of common stock for $10.35 per share under a Rule 10b5-1 trading plan.

Summary

• Steve Pakola, Chief Medical Officer of REGENXBIO Inc. (RGNX), disposed of 5,124 shares of common stock.
• The transaction occurred on March 10, 2026, at a price of $10.35 per share.
• The sale was executed pursuant to a pre-arranged Rule 10b5-1 trading plan.
• Following this transaction, Mr. Pakola beneficially owns 247,926 shares of REGENXBIO common stock.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a moderately negative signal. While the sale was pre-planned under Rule 10b5-1, the disposition of shares by a senior executive can still be interpreted by the market as a lack of strong conviction in the stock's near-term appreciation.

Negatives

• The Chief Medical Officer sold 5,124 shares of company common stock.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that insider selling, even when conducted under a Rule 10b5-1 plan, is often scrutinized by investors as it can be perceived as a signal regarding management's view on the company's valuation or future prospects. While 10b5-1 plans are designed to avoid accusations of trading on material non-public information, the underlying action of selling shares by a key executive in the biotechnology sector can still draw attention, especially given the inherent volatility and long development cycles in the industry.

Stakeholder Impact

• Shareholders may interpret the insider sale as a negative signal regarding the company's future prospects or current valuation, potentially influencing their investment decisions.

Key Dates

Recommendation

A single insider sale, even by a key executive, especially when conducted under a Rule 10b5-1 plan, is not typically a strong enough signal on its own to warrant an immediate 'sell' recommendation. While it introduces a degree of caution, it's prudent for investors to 'hold' and monitor for further insider activity or other fundamental company news before making a definitive change to their position. The pre-planned nature mitigates some of the immediate negative implications.

Keywords

REGENXBIO, RGNX, Insider Sale, Form 4, Rule 10b5-1, Steve Pakola, Chief Medical Officer, Stock Transaction